
VISIONARY 2-Year eGFR Data in IgA Nephropathy
0:00
37:57
Hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, welcome Dana Rizk, MD, professor of medicine in the Division of Nephrology at the University of Alabama at Birmingham. Rizk walks through the 24-month eGFR and safety findings from the phase 3 VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy (IgAN) in the lastest episode of Kidney Compass.
Fler avsnitt från "Kidney Compass: Navigating Clinical Trials"



Missa inte ett avsnitt av “Kidney Compass: Navigating Clinical Trials” och prenumerera på det i GetPodcast-appen.








